Search results for " Kidney disease"

showing 10 items of 160 documents

COVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos?

2020

La pandemia SARS-CoV-2 es una emergencia sanitaria global y necesitamos conocer más sobre ella. Los pacientes con riesgo cardiovascular y renal previo se han identificado como especialmente vulnerables para una mayor morbimortalidad cuando sufren la COVID-19, y una proporción considerable de pacientes pueden desarrollar una lesión vascular en el contexto de la enfermedad que conlleva una mayor letalidad. Las complicaciones cardiovasculares y renales representan un problema, y es probable que en un futuro próximo puedan suponer una amenaza para los pacientes que han sobrevivido a la COVID-19. Como médicos no podemos olvidar que durante una epidemia como esta otras enfermedades ----crónicas--…

medicine.medical_specialtyPopulationmorbidityContext (language use)Disease030204 cardiovascular system & hematologyenfermedad renal crónica03 medical and health sciences0302 clinical medicinecardiovascular diseaseNeed to knowPandemicGlobal healthMedicinemorbilidad030212 general & internal medicineIntensive care medicineeducationeducation.field_of_studybusiness.industryPublic Health Environmental and Occupational HealthCOVID-19medicine.diseasemortalitymortalidadLevel of careFamily Practicebusinessenfermedad cardiovascularchronic kidney diseaseKidney diseaseMedicina de Familia. SEMERGEN
researchProduct

A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?

2013

article i nfo Introduction: The efficacy of statin treatment in chronic kidney disease (CKD) patients remains controversial. Therefore, we performed a meta-analysis to investigate whether statins modulate renal function in patients with CKD. Methods: Data from Scopus, PubMed, Web of Science, and the Cochrane Central Register of randomized controlled trials for years 1966-December 2012 were searched for appropriate studies. Results: Twenty trials with 6452 CKD subjects randomized to receive either statin or placebo were included. Statin therapy significantly influenced high sensitivity C-reactive protein levels in patients on or off dialysis (−0.28 mg/dl, 95%CI: −0.93 to −0.37; p b 0.05 and …

medicine.medical_specialtyStatinmedicine.drug_classmedicine.medical_treatmentRenal functionPlaceboGastroenterologyBlood Urea Nitrogenlaw.inventionchemistry.chemical_compoundRandomized controlled trialRenal DialysislawInternal medicinemedicineHumansRenal Insufficiency ChronicIntensive care medicinechronic kidney disease creatinine dialysis meta-analysis renal outcomes statin urinary proteinDialysisRandomized Controlled Trials as TopicCreatininebusiness.industrymedicine.diseaseTreatment OutcomechemistryCardiovascular DiseasesCreatinineMeta-analysisHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessGlomerular Filtration RateKidney disease
researchProduct

Expression of differentiation antigens and growth-related genes in normal kidney, autosomal dominant polycystic kidney disease, and renal cell carcin…

1992

Cellular differentiation and mRNA levels of genes involved in kidney growth were investigated in normal kidney cells, cyst-lining epithelial cells of polycystic kidney disease, and renal carcinoma cells (RCC). All cells comparatively studied exhibited an antigenic phenotype of proximal tubular cells as shown by the expression of a panel of brush border membrane enzymes and kidney-associated cell surface antigens. The epithelial developmental antigen Exo-1 was expressed in 50% to 80% of cyst-lining epithelia in polycystic kidney tissue and in 20% to 30% of polycystic kidney cells cultured in vitro. Normal kidney cells and RCC were negative under identical culture conditions. The expression o…

medicine.medical_specialtyTGF alphaCellular differentiationAutosomal dominant polycystic kidney diseaseGene ExpressionBiologyKidneyEpitheliumProto-Oncogene Proteins c-mycGrowth factor receptorEpidermal growth factorInternal medicinemedicinePolycystic kidney diseaseHumansRNA MessengerGrowth SubstancesCarcinoma Renal CellCells CulturedKidneyurogenital systemAntibodies MonoclonalTransforming Growth Factor alphamedicine.diseasePolycystic Kidney Autosomal DominantAntigens DifferentiationImmunohistochemistryKidney NeoplasmsErbB ReceptorsEndocrinologymedicine.anatomical_structureGenesNephrologyAntigens SurfaceCancer researchTransforming growth factorAmerican journal of kidney diseases : the official journal of the National Kidney Foundation
researchProduct

Kidney Disease Management in the Hospital Setting: A Focus on Inappropriate Drug Prescriptions in Older Patients

2021

Aging with multimorbidity and polytherapy are the most significant factors that could led to inappropriate prescribing of contraindicated medications in patients with chronic kidney disease (CKD). The aim of this study was to evaluate the prescriptions of contraindicated drugs in older adults in CKD and to identify their associated factors in a hospital context. An observational retrospective study was carried out considering all patients ≥65 years with at least one serum creatinine value recorded into the REPOSI register into 2010–2016 period. The estimated glomerular filtration rate (eGFR) was applied to identify CKD. A descriptive analysis was performed to compare demographic and clinica…

medicine.medical_specialtyappropriateness of prescriptionprescribing patternsRenal functionContext (language use)RM1-950Logistic regressionNOchemistry.chemical_compoundolder patientInternal medicinehospital settingmedicinePharmacology (medical)LS4_4Medical prescriptionprescribing patternappropriateness of prescriptions chronic kidney disease hospital setting older patients prescribing patterns real-world data.Original ResearchPharmacologyCreatininereal-world databusiness.industryRetrospective cohort studymedicine.diseaseolder patientsreal-world data.appropriateness of prescriptions; chronic kidney disease; hospital setting; older patients; prescribing patterns; real-world dataappropriateness of prescriptionschemistryObservational studyTherapeutics. Pharmacologybusinesschronic kidney diseaseKidney diseaseFrontiers in Pharmacology
researchProduct

Hepatitis C virus infection and global kidney health: the consensus proceedings of the International Federation of Kidney Foundations

2020

Hepatitis C virus (HCV) infection is an important cause of major morbidities including chronic liver disease, liver cancer, and acute kidney injury (AKI) as well as chronic kidney disease (CKD). HCV can affect kidney health; among CKD and AKI patients with HCV infection, the clinical outcomes are worse. The prevalence of HCV infection is exceptionally high among dialysis and kidney transplant patients throughout the globe. It is estimated that 5% to 25% or more of dialysis dependent patients are affected by chronic HCV, based on the region of the world. Almost half of all deaths in CKD patients, including HCV-infected patients, are due to cardiovascular disease, and HCV infected patients ha…

medicine.medical_specialtybusiness.industryHepatitis C virusmedicine.medical_treatmentPublic healthAcute kidney injuryvirus diseasesDiseaseurologic and male genital diseasesmedicine.disease_causemedicine.diseaseChronic liver diseaseArticledigestive system diseasesPsychiatry and Mental healthNeuropsychology and Physiological PsychologyInternal medicineAfricamedicinehepatitis C virus infectionViral hepatitisbusinesschronic kidney diseaseDialysisKidney diseaseAfrican Journal of Nephrology
researchProduct

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19

2020

Hospital admissions and mortality from the Coronavirus disease 2019 (COVID-19) pandemic are spreading throughout the world, and second and third waves are thought to be likely. Risk factors for severe COVID-19 include diabetes, chronic kidney disease and cardiovascular disease. Currently, there is no vaccine and no approved therapy. Therapeutic approaches are aimed at preventing viral replication and spread, limiting the impact of the inflammatory overdrive (cytokine storm), preventing thromboembolic complications and replacing or supporting organ function. However, despite organ support, mortality is currently 65% for those receiving advanced respiratory support and 78% for those requiring…

medicine.medical_specialtyempagliflozinEmpagliflozinlcsh:MedicineContext (language use)ReviewDisease030204 cardiovascular system & hematologyCardiovascularSGLT203 medical and health scienceschemistry.chemical_compound0302 clinical medicineChronic kidney diseaseDiabetes mellitusmedicine030212 general & internal medicineCanagliflozinDapagliflozincanagliflozinIntensive care medicinediabetesbusiness.industrycardiovascularDiabeteslcsh:RCOVID-19dapagliflozinGeneral MedicineDapagliflozinmedicine.diseaseVirusClinical trialRespiratory failurechemistryCytokine stormbusinesschronic kidney diseaseKidney diseaseJournal of Clinical Medicine
researchProduct

Blood pressure in chronic kidney disease stage 5D—report from a Kidney Disease: Improving Global Outcomes controversies conference

2010

Management of blood pressure (BP) in patients with chronic kidney disease receiving dialysis (stage 5D) provides a significant challenge for healthcare professionals. The association between BP and cardiovascular disease risk has been well studied in the general population; however, in dialysis patients, physiological and dialysis-related mechanisms influencing BP are complex, and the associated risk is poorly understood. In stage 5D, BP is determined by the complex interplay of fluid volume and prescription of post-dialysis target weight, sodium load, the renin–angiotensin and sympathetic nervous systems, and diverse exogenous factors, such as administration of erythropoiesis-stimulating a…

medicine.medical_specialtyhypotensionhypertensionmedicine.medical_treatmentPopulationLeft ventricular hypertrophylaw.inventionRandomized controlled triallawMedicineantihypertensiveMedical prescriptioneducationIntensive care medicinesodium managementDialysiseducation.field_of_studybusiness.industryGuidelinemedicine.diseaseBlood pressureNephrologydialysisbusinesschronic kidney diseaseKidney diseaseKidney International
researchProduct

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

2015

Current therapy directed at delaying the progression of diabetic nephropathy includes intensive glycemic and optimal blood pressure control, renin angiotensin-aldosterone system blockade and multifactorial intervention. However, the renal protection provided by these therapeutic modalities is incomplete. There is a scarcity of studies analysing the nephroprotective effect of antihyperglycaemic drugs beyond their glucose lowering effect and improved glycaemic control on the prevention and progression of diabetic nephropathy. This article analyzes the exisiting data about older and newer drugs as well as the mechanisms associated with hypoglycemic drugs, apart from their well known blood gluc…

medicine.medical_specialtylcsh:MedicineReviewPharmacologyalbuminuriaDiabetic nephropathyDDP4 inhibitorsDiabetes mellitusantihyperglycemic drugsSGLT2 inhibitionRenin–angiotensin systemDiabetic nephropathiesmedicineIntensive care medicineGlycemicnephroprotectionKidneyDiabetisdiabetic chronic kidney diseasebusiness.industrydiabetic nephropathylcsh:RDiabetesGeneral MedicineNefropaties diabètiquesmedicine.diseaseBlockadeClinical trialmedicine.anatomical_structurediabetes mellitusAlbuminuriaglucagon-like peptide agonistsmedicine.symptombusiness
researchProduct

Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involvin…

2013

The available studies have reported the benefits of statins on all-cause and cardiovascular mortality in chronic kidney disease (CKD) patients. However studies in end-stage renal disease patients on dialysis yielded conflicting results. Therefore, we performed a meta-analysis and provide the most reliable trial data to date on the impact of statin therapy on cardiovascular events and death from all causes in CKD patients. Data from PubMed, Web of Science, Cochrane Library, and Scopus for the years 1966 to October 2012 were searched. The final meta-analysis included 11 randomized controlled trials involving 21,295 participants with CKD. Among them 6857 were on dialysis. The use of statins in…

medicine.medical_specialtymedicine.medical_treatmentDiseaseCochrane Librarylaw.inventionRandomized controlled triallawRenal DialysisInternal medicinemedicineHumansRenal Insufficiency ChronicIntensive care medicineDialysisRandomized Controlled Trials as TopicPharmacologybusiness.industrymedicine.diseaseConfidence intervalCardiovascular events Chronic kidney disease Dialysis Mortality Statins StrokeStrokeCardiovascular DiseasesMeta-analysisRelative riskHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessKidney diseasePharmacological research
researchProduct

Prevalence of Vertebral Fractures and Their Prognostic Significance in the Survival in Patients with Chronic Kidney Disease Stages 3‒5 Not on Dialysis

2020

Background: The prevalence of vertebral fractures (VF) and their association with clinical risk factors and outcomes are poorly documented in chronic kidney disease (CKD) cohorts. The aim of the study was to evaluate the prevalence of VF in patients with non-dialysis dependent CKD (NDD-CKD), their value in predicting mortality and its correlation with parameters of bone mineral metabolism and vascular calcification. Materials and Methods: 612 NDD 3‒5 stage CKD patients participating in the OSERCE-2 study, a prospective, multicenter, cohort study, were prospectively evaluated and categorized into two groups according to presence or absence of VF at enrollment. VF were assessed with lateral r…

medicine.medical_specialtymedicine.medical_treatmentOsteoporosis030232 urology & nephrologylcsh:Medicine030209 endocrinology & metabolismLogistic regressionArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineRisk factorSurvival analysisDialysisVascular diseasebusiness.industrylcsh:RGeneral Medicinefracturesmedicine.diseasevascular calcificationbusinesschronic kidney diseaseCohort studyKidney diseaseJournal of Clinical Medicine
researchProduct